At the core of MD Anderson’s approach to exceptional patient care is a virtuous cycle of innovation that's grounded in collaboration, connectivity and data-based science. Our unique environment and vast resources accelerate novel concepts faster than ever before by offering leading scientific minds close proximity to our clinics to ease collaboration with our renowned clinicians and our patient partners.
At the 2023 American Association for Cancer Research Annual Meeting, our experts will showcase their pacesetting research and join colleagues from across the globe for discussion on the latest advances in cancer science.
Below are highlights from our presentations, details about onsite networking opportunities with our experts and information on open research positions at MD Anderson.
Single-cell study uncovers distinct immunosuppressive tumor microenvironment in brain metastases from kidney cancer
Comprehensive analysis highlights differences between brain metastases and other tumor sites, identifying potential therapeutic targets
Early trial results show benefits of FGFR inhibitors and PARP/ATR inhibitor combinations in multiple tumor types
MD Anderson researchers present targeted therapy results from two clinical trial findings
Mutations in three key genes associated with poor outcomes in lung cancer patients treated with KRAS G12C inhibitors
Study provides framework for personalizing treatment approaches and developing combination strategies for KRAS G12C-mutant lung cancer
Meet the Experts
Visit booth 1501 to discuss hot topics and emerging trends with leading minds in cancer science.
Sunday, April 16
Targeting cell adhesion molecule 1 (CADM1) with an antibody drug conjugate for the treatment of osteosarcoma (Abstract 1202)
Richard Gorlick, M.D.
Yifei Wang, M.D.
Advances in neoadjuvant therapies/immunotherapies
Monday, April 17
Accelerated cardiac aging in adolescent and young adult cancer survivors previously treated with cardiotoxic therapy (Abstract 5759)
A phase I multicenter study (TRAVERSE) evaluating the safety and efficacy of ALLO-316 following conditioning regimen in pts with advanced or metastatic clear cell renal cell carcinoma (ccRCC) (Abstract CT011)
Clinical trials at MD Anderson
David Hong, M.D.
Jennifer Litton, M.D.
Timothy Yap, M.D., Ph.D.
Tuesday, April 18
The interception of precancers
Nicholas Navin, Ph.D.
Eduardo Vilar-Sanchez, M.D., Ph.D.
Jianjun Zhang, M.D., Ph.D.
Discovery research at MD Anderson
Eyal Gottlieb, Ph.D.
Humam Kadara, Ph.D.
Raghu Kalluri, M.D., Ph.D.
Clinical and translational findings of pemigatinib in previously treated solid tumors with activating FGFR1-3 alterations in the FIGHT-207 study (Abstract CT016)
Jordi Rodon Ahnert, M.D., Ph.D.
Targeting oncogenic RAS mutations
Tim Heffernan, Ph.D.
John Heymach, M.D., Ph.D.
Scott Kopetz, M.D., Ph.D.
Ferdinandos Skoulidis, M.D., Ph.D.
Our research by the numbers
invested in research
From Sept. 1, 2021-Aug. 31, 2022.
Education and Training at MD Anderson
MD Anderson academic programs are competitive and comprehensive. We offer educational opportunities from undergraduate degrees to postdoctoral training.
James P. Allison Institute
The James P. Allison Institute is dedicated to advancing exceptional discovery, translational and clinical research to integrate immunobiology across disciplines and unlock the full potential of science and medicine for human health. The institute builds upon the legacy of its namesake, James P. Allison, Ph.D., who was awarded the 2018 Nobel Prize in Physiology or Medicine for his fundamental discoveries in T cell biology and his invention of ipilimumab, the first immune checkpoint inhibitor to treat cancer.
Meet Dr. James Allison at the 2023 AACR Annual Meeting on Tuesday, April 18 from 3-4 p.m.
Our Therapeutics Discovery team consists of dedicated cancer researchers, doctors, drug developers and scientific experts. We develop small molecule drugs, biologics and cellular therapies without the bottlenecks that hamper traditional drug development.
We're inspired by the needs of our patients and guided by the expertise of MD Anderson clinicians. We don't bring the “bench to bedside” – we start with the bench at the bedside – with each patient and their cancer.
As America's fourth largest city, Houston has a lot to offer. Find out why Houston is a hub for scientific and medical excellence.